In accordance with previous findings that TDEs substantially increased the expression of PD-L1 on DCs (Figure 2A), we hypothesized that PPARα inhibition combined with PD-L1 blockade may initiate more powerful anti-tumor efficacy. The gene discussed is CD274; the disease is neoplasm.